4-fluoro-N-methyl-3-(trifluoromethyl)aniline

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-fluoro-N-methyl-3-(trifluoromethyl)aniline
• 化学式: C₈H₇F₄N
• 分子量: 193.144
• InChiKey: PIRDWQBTHFZINC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-fluoro-N-methyl-3-(trifluoromethyl)aniline 、 1-naphthylcyanamide 在 盐酸 作用下， 以 乙醚 、 水 、 甲苯 为溶剂， 反应 21.0h， 以58%的产率得到1-(4-fluoro-3-(trifluoromethyl)phenyl)-1-methyl-3-(naphthaalen-1-yl)guanidine
  参考文献：
  名称：

  N′-3-(Trifluoromethyl)phenyl Derivatives of N-Aryl-N′-methylguanidines as Prospective PET Radioligands for the Open Channel of the N-Methyl-d-aspartate (NMDA) Receptor: Synthesis and Structure–Affinity Relationships

  摘要：

  N-Methyl-D-aspartate (NMDA) receptor dysfunction has been linked to several neuropsychiatric disorders, including Alzheimer's disease, epilepsy, drug addiction, and schizophrenia. A radioligand that could be used with PET to image and quantify human brain. NMDA receptors in the activated "open channel" state would be useful for research on such disorders and for the development of novel therapies,: To date, no radioligands have Shown well-validated efficacy for imaging NMDA receptors in human subjects. In order to discover improved radioligands for PET imaging, we explored structure affinity relationships in N'-3-(trifluoromethyl)phenyl derivatives of N-aryl-N'-methylguanidines, seeking high affinity and moderate lipophilicity, plus necessary amenability for labeling with a positron-emitter, either carbon-11 or fluorine-18. Among a diverse set of 80 prepared N'-3-(trifluoromethyl)phenyl derivatives, four of these compounds (13, 19, 20, and 36) displayed desirable low nanomolar affinity for inhibition of [H-3](+)-MK801 at the PCP binding site and are of interest for candidate PET radioligand development.

  DOI：

  10.1021/acs.jmedchem.5b01510
• 作为产物：
  描述：

  4-氟-3-三氟甲基苯胺 、 原甲酸三甲酯 在 硫酸 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 5.5h， 以55%的产率得到4-fluoro-N-methyl-3-(trifluoromethyl)aniline
  参考文献：
  名称：

  N′-3-(Trifluoromethyl)phenyl Derivatives of N-Aryl-N′-methylguanidines as Prospective PET Radioligands for the Open Channel of the N-Methyl-d-aspartate (NMDA) Receptor: Synthesis and Structure–Affinity Relationships

  摘要：

  N-Methyl-D-aspartate (NMDA) receptor dysfunction has been linked to several neuropsychiatric disorders, including Alzheimer's disease, epilepsy, drug addiction, and schizophrenia. A radioligand that could be used with PET to image and quantify human brain. NMDA receptors in the activated "open channel" state would be useful for research on such disorders and for the development of novel therapies,: To date, no radioligands have Shown well-validated efficacy for imaging NMDA receptors in human subjects. In order to discover improved radioligands for PET imaging, we explored structure affinity relationships in N'-3-(trifluoromethyl)phenyl derivatives of N-aryl-N'-methylguanidines, seeking high affinity and moderate lipophilicity, plus necessary amenability for labeling with a positron-emitter, either carbon-11 or fluorine-18. Among a diverse set of 80 prepared N'-3-(trifluoromethyl)phenyl derivatives, four of these compounds (13, 19, 20, and 36) displayed desirable low nanomolar affinity for inhibition of [H-3](+)-MK801 at the PCP binding site and are of interest for candidate PET radioligand development.

  DOI：

  10.1021/acs.jmedchem.5b01510

文献信息

• [EN] BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES BICYCLIQUES ET LEUR UTILISATION EN TANT QUE MODULATEURS DE GPR119
  申请人：SCHERING CORP

  公开号：WO2009143049A1

  公开（公告）日：2009-11-26

  The present invention relates to Bicyclic Heterocycle Derivatives of formula (I), compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR1 19 in a patient.

  本发明涉及公式（I）的双环杂环衍生物，包含双环杂环衍生物的组合物，以及使用双环杂环衍生物治疗或预防患者的肥胖、糖尿病、代谢紊乱、心血管疾病或与GPR119活性相关的疾病的方法。
• [EN] NOVEL PYRIDAZONES AND TRIAZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION<br/>[FR] NOUVELLES PYRIDAZONES ET TRIAZINONES POUR LE TRAITEMENT ET LA PRÉVENTION DE L'INFECTION PAR LE VIRUS DE L'HÉPATITE B
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016023877A1

  公开（公告）日：2016-02-18

  The invention provides novel compounds having the general formula wherein R1, R2, R3, X and a are as described in the description and in the claims, as well as or pharmaceutically acceptable salts thereof. The invention also contains compositions including the compounds and methods of using the compounds.

  这项发明提供了具有一般公式的新化合物，其中R1、R2、R3、X和a如描述和索赔中所述，以及其药学上可接受的盐。该发明还包括包括这些化合物的组合物和使用这些化合物的方法。
• Aryl-substituted pyrimidines as insecticidal and acaricidal agents
  申请人：American Cyanamid Company

  公开号：US06153619A1

  公开（公告）日：2000-11-28

  There are provided compositions and methods comprising compounds of formula I: ##STR1## wherein R.sup.1, A, B, X, Y and Z have the meaning given in claim 1, for the control of insect and acarid pests.

  提供了包含式I的化合物和方法，其中R.sup.1、A、B、X、Y和Z的含义如索赔1所述，用于控制昆虫和螨虫害。
• Use of aryl-substituted pyrimidines as insecticidal and acaricidal agents
  申请人：American Cyanamid Company

  公开号：US20020045634A1

  公开（公告）日：2002-04-18

  There are provided compositions and methods comprising compounds of formula I: 1 wherein R 1 , A, B, X, Y and Z have the meaning given in claim 1, for the control of insect and acarid pests.

  提供了一种由I式化合物组成的组合物和方法：1其中R1、A、B、X、Y和Z的含义如权利要求1所述，用于控制昆虫和螨虫害。
• Quinoline derivatives as phosphodiesterase inhibitors
  申请人：Baldwin Robert Ian

  公开号：US20070142373A1

  公开（公告）日：2007-06-21

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R 1 , R 2, R 19, R 20, and R 34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了新型化合物(I)的公式或其药学上可接受的盐，其中R1、R2、R19、R20和R34如规范所述，制备它们的过程，含有它们的配方以及它们在治疗炎症性疾病中的用途。